Home/Biosimilar Atlas/Rituximab/Reliance Life Sciences rituximab

Reliance Life Sciences rituximab

Rituximab biosimilar developed by Reliance Life Sciences. Reference product MabThera (Rituxan in the United States).

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Reliance Life Sciences · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOFeb 2015permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
RituximabmoleculeReliance Life Sciencesdeveloper1 of 7markets0trials behind it13other products, same developer6rival developers in its markets

About Reliance Life Sciences rituximab

Reliance Life Sciences received its rituximab permission in India in February 2015, covering lymphoma, leukaemia and rheumatoid arthritis. It is one of the broadest Indian rituximab labels.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Reliance Life Sciences Pvt Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Feb 2015
Application or permission
MF-17/2015; BULK-16/2015
Indications as licensed
NHL, CLL, RA
Presentations
100 mg/10 mL and 500 mg/50 mL vials
Source
S014 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Reliance Life Sciences rituximab holds an approval, these are the other rituximab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO6Biocad (Biocad rituximab), Hetero (Hetero rituximab), Intas Pharmaceuticals (Intas rituximab), Virchow Biotech (Virchow Biotech rituximab), Zenotech Laboratories (Zenotech rituximab), Zydus Lifesciences (Zydus rituximab)

Same developer, other molecules

Other biosimilars in the Atlas developed by Reliance Life Sciences: Reliance Life Sciences adalimumab, Reliance Life Sciences bevacizumab, Reliance Life Sciences darbepoetin alfa, Reliance Life Sciences denosumab, Reliance Life Sciences etanercept, Reliance Life Sciences follitropin alfa, Reliance Life Sciences golimumab, Reliance Life Sciences infliximab, Reliance Life Sciences omalizumab, Reliance Life Sciences ranibizumab, Reliance Life Sciences somatropin, Reliance Life Sciences trastuzumab, UstekiRel.

Chronology

Sources

All rituximab biosimilars

Planning rituximab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.